(PSNL) – StreetInsider.com Reports
-
Personalis (PSNL) PT Raised to $3.50 at Needham, '4Q23 Consistent with Preannouncement; Aiming for $100M of Sales in 2025'
-
Personalis, Inc. (PSNL) Misses Q4 EPS by 4c, provides guidance
-
Personalis (PSNL) Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
-
Personalis, Inc. (PSNL) Files For 9.22M Share Offering by Selling Stockholders
-
Personalis, Inc. (PSNL) Files $200M Mixed Shelf
-
Personalis, Inc. (PSNL) discloses reduction in headcount impacting approximately 20%
-
Personalis, Inc. (PSNL) and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
-
Myriad Genetics (MYGN) and Personalis Partner to Market Solutions to Pharma Customers
-
Personalis (PSNL) PT Lowered to $2.30 at Needham & Company
-
Personalis, Inc. (PSNL) Misses Q3 EPS by 8c
-
Personalis (PSNL) Launches NeXT Personal Dx for Early Access Clinical Use
-
Personalis, Inc. (PSNL) Tops Q2 EPS by 4c ; offers guidance
-
Personalis (PSNL) Files Second Patent Infringement Suit Against Foresight Diagnostics
-
Personalis, Inc. (PSNL) Appoints Kenneth J. Widder to its Board
-
Personalis (PSNL) PT Lowered to $7 at Needham & Company
-
Personalis, Inc. (PSNL) Misses Q1 EPS by 3c
-
Personalis, (PSNL) ABRCC and Criterium Announce Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
-
Personalis (PSNL) will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement
-
Personalis, Inc. (PSNL) Appoints Christopher Hall as CEO
-
Personalis (PSNL) PT Lowered to $5 at Morgan Stanley
-
Personalis (PSNL) PT Lowered to $5 at BTIG
-
Personalis (PSNL) PT Lowered to $10 at H.C. Wainwright
-
Personalis, Inc. (PSNL) Misses Q4 EPS by 3c; Guides Below Views
-
Needham & Company Upgrades Personalis (PSNL) to Buy
-
Personalis (PSNL), Moderna (MRNA) Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
-
After-hours movers: Geron lower on offering, Inter Parfums gains on raised guidance
-
Personalis, Inc. (PSNL) Prelim. Q4 Revenue Tops Consensus
-
Personalis, Inc. (PSNL) and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
-
Personalis (PSNL) PT Lowered to $8 at BTIG
-
Personalis (PSNL) PT Lowered to $13 at H.C. Wainwright
-
Personalis (PSNL) PT Lowered to $5 at BofA Securities
-
Personalis (PSNL) PT Lowered to $6 at Citi
-
Personalis (PSNL) PT Lowered to $11 at BTIG
-
Personalis (PSNL) Files Patent Infringement Lawsuit Against Foresight Diagnostics
-
Personalis (PSNL) PT Lowered to $6 at BofA Securities
-
Personalis (PSNL) Granted New Patent Related to Tumor-Informed Detection of Molecular Residual Disease
-
Personalis (PSNL) PT Lowered to $15 at BTIG
-
Personalis (PSNL) Reports Publication of New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
-
Personalis (PSNL) PT Lowered to $38 at H.C. Wainwright
-
Personalis (PSNL) PT Lowered to $18 at Citi
-
Personalis (PSNL) PT Lowered to $24 at Oppenheimer
-
Personalis, Inc. (PSNL) Tops Q4 EPS by 5c
-
Personalis, Inc. (PSNL) Launches NeXT Personal, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
-
Morgan Stanley Downgrades Personalis (PSNL) to Equalweight, Following Earnings
-
Personalis (PSNL) PT Raised to $30 at Oppenheimer, Following Earnings
-
Personalis, Inc. (PSNL) Tops Q3 EPS by 2c
-
UPDATE: Needham & Company Downgrades Personalis (PSNL) to Hold
-
Personalis (PSNL) Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
-
Cowen Assumes Personalis (PSNL) at Outperform
-
Personalis, Inc. (PSNL) Collaborates with Mayo Clinic to Expand Cancer Genomic Testing
Back to PSNL Stock Lookup
